聯影醫療(688271.SH):在MI方面將持續在高性能長軸系統、腦部專用機以及診療一體化應用等方面發力
格隆匯5月16日丨聯影醫療(688271.SH)於2023年4月29日、5月7日參加分析師會議、電話會議或者召開業績説明會,公司表示,在MI方面,繼在2022年向市場推出業界全面領先的uMIPanorama產品系列之後,公司將持續在高性能長軸系統、腦部專用機以及診療一體化應用等方面發力,同時也將繼續拓展在PET技術平台和下一代性價比突出的PET探測器的開發。
未來公司的PET/MR產品線也將推出具有更快掃描速度、更優圖像質量、更低輻射劑量和更便捷臨牀工作流的產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.